
A biology student became a lawyer, a lawyer became an operator, and an operator built a biotech company around a neglected question: what changes when metabolism is treated as part of the therapeutic design?
Single-target cancer drugs can teach tumors how to route around them. Faeth’s answer is PIKTOR - two oral medicines, three pathway nodes and a public-company-sized test of whether deeper blockade can stay tolerable.